Drugs / Hydrocortisone
Hydrocortisone
also known as
Hydrocortisone sodium succinate · hydrocortisone acetate · solu-cortef · Cortef · HYDROCORTISONE HEMISUCCINATE · Plenadren · cortisol · Infacort · +21 more
Regulatory milestones approvals, filings & regulatory actions · 2 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | EU (EMA) | Plenadren | — | 2011-11-03 | europa.eu ↗ |
| Approved | US (FDA) | HYDROCORTONE | — | 1951-12-21 | fda.gov ↗ |
Trials 207 · started per year
today
US approved 1951
EU approved 2011
1
2
1
1
1
5
4
3
5
8
5
17
12
8
5
12
4
5
11
14
6
13
12
10
7
8
4
8
6
9
195019511952195319541955195619571958195919601961196219631964196519661967196819691970197119721973197419751976197719781979198019811982198319841985198619871988198919901991199219931994199519961997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027202820292030
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 013 trials · 1 met primary | ||||||
| Phase 0 | NCT07612631 | Jun 2026 → Jun 2031 expected | alcohol-related disorders | Rajesh Narendran | Recruiting | No outcome recorded |
| Phase 0 | NCT06430580 | Sep 2024 → Sep 2026 overdue | cannabis dependence | Florida State University | Recruiting | No outcome recorded |
| Phase 0 | NCT05919992 | May 2023 → Jul 2024 | glucocorticoid therapy, response to | Eleonora Seelig | Completed | No outcome recorded |
| Phase 0 | NCT05167084 | Feb 2022 → Jun 2023 | glucocorticoid therapy, response to | Eleonora Seelig | Completed | No outcome recorded |
| Phase 0 | NCT04896489 | May 2021 → Mar 2022 | alcohol-related disorders | Yale University | Completed | No outcome recorded |
| Phase 0 | NCT04148261 | Dec 2020 → Dec 2022 | depressive disorder | Stanford University | Withdrawn | No outcome recorded |
| Phase 0 | NCT04037605 | Feb 2020 → Jul 2022 overdue | — | Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center | Active not recruiting | No outcome recorded |
| Phase 0 | NCT04435912 | Jul 2019 → Apr 2020 | — | University of Jordan | Completed | No outcome recorded |
| Phase 0 | NCT01422733 | Jun → Jul 2018 | obesity disorder, polycystic ovary syndrome | University of Virginia | Withdrawn | No outcome recorded |
| Phase 0 | NCT01422707 | Jan → Jul 2018 | obesity disorder, polycystic ovary syndrome | University of Virginia | Withdrawn | No outcome recorded |
| Phase 0 | NCT03237689 | Nov 2017 → Sep 2023 | HIV infectious disease | Johns Hopkins University | Completed | No outcome recorded |
| Phase 0 | NCT02837432 | Jul 2016 → Dec 2019 | depressive disorder | Stanford University | Completed | No outcome recorded |
| Phase 0 | NCT03302416 | Jun 2016 → Jun 2019 | — | University of Pittsburgh | Completed | Met primary |
| Phase 115 trials · 1 missed | ||||||
| Phase 1 | NCT07796997 | Sep 2026 → Oct 2028 expected | duodenum cancer, extrahepatic bile duct carcinoma, pancreatic adenocarcinoma | University of Illinois at Chicago | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT04852458 | May 2021 → Nov 2022 | — | University of Michigan | Completed | Missed primary |
| Phase 1 | NCT03718234 | Jan 2019 → Feb 2023 | adrenal gland hyperfunction, congenital adrenal hyperplasia, disorder of sexual differentiation, hyperplasia +1 | University of Minnesota | Completed | No outcome recorded |
| Phase 1 | NCT03311932 | Apr → Jul 2018 | adrenocortical insufficiency | Neurocrine UK Limited | Completed | No outcome recorded |
| Phase 1 | NCT03343327 | Feb → Apr 2018 | adrenocortical insufficiency | Neurocrine UK Limited | Completed | No outcome recorded |
| Phase 1 | NCT03178214 | May → Jul 2017 | adrenocortical insufficiency | Neurocrine UK Limited | Completed | No outcome recorded |
| Phase 1 | NCT03142893 | May 2017 → Oct 2020 overdue | — | Peter y. Liu | Active not recruiting | No outcome recorded |
| Phase 1 | NCT02722200 | May 2016 → Jul 2017 | obesity disorder | Yale University | Completed | No outcome recorded |
| Phase 1 | NCT02671058 | Mar → May 2016 | — | Cristcot LLC | Completed | No outcome recorded |
| Phase 1 | NCT03670212 | Jan → Oct 2016 | — | Wayne State University | Completed | No outcome recorded |
| Phase 1 | NCT01960530 | Oct 2013 → Nov 2014 | adrenocortical insufficiency | Neurocrine UK Limited | Completed | No outcome recorded |
| Phase 1 | NCT01265017 | Jul 2012 → Jun 2020 | type 1 diabetes mellitus | Sansum Diabetes Research Institute | Withdrawn | No outcome recorded Stop: Business |
| Phase 1 | NCT03051893 | Feb 2011 → Apr 2012 | congenital adrenal hyperplasia | Neurocrine UK Limited | Completed | No outcome recorded |
| Phase 1 | NCT03019614 | Mar → Apr 2010 | congenital adrenal hyperplasia | Neurocrine UK Limited | Completed | No outcome recorded |
| Phase 1 | NCT01055249 | Jan → Jun 2010 | — | X-pert Med GmbH | Completed | No outcome recorded |
| Phase 1/29 trials · 1 missed | ||||||
| Phase 1/2 | NCT05157360 | Sep 2021 → May 2023 | infectious disease with sepsis, necrotizing soft tissue infection | Ascension Health | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1/2 | NCT03649633 | Sep 2018 → Jan 2023 | infectious disease with sepsis | University of Athens | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1/2 | NCT03015246 | Dec 2016 → Jun 2020 | heroin dependence | Wayne State University | Completed | No outcome recorded |
| Phase 1/2 | NCT02790788 | Nov 2016 → May 2018 | cardiac arrest | University of Athens | Completed | Mixed |
| Phase 1/2 | NCT02096510 | Mar 2014 → Dec 2016 | congenital adrenal hyperplasia | Haukeland University Hospital | Completed | No outcome recorded |
| Phase 1/2 | NCT02922374 | Jan 2013 → Jun 2016 | colitis | Jinling Hospital, China | Unknown | No outcome recorded |
| Phase 1/2 | NCT00673270 | May → Oct 2008 | hypertensive disorder | Rennes University Hospital | Terminated | No outcome recorded |
| Phase 1/2 | NCT00676585 | Oct 2007 → Apr 2014 | cardiac arrest | Beth Israel Deaconess Medical Center | Completed | Missed primary |
| Phase 1/2 | NCT00519818 | Aug 2007 → May 2009 | classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency | Neurocrine UK Limited | Completed | No outcome recorded |
| Phase 239 trials · 1 met primary · 3 missed | ||||||
| Phase 2 | NCT04231708 | Oct 2026 → Dec 2028 expected | substance-related disorder | Wayne State University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07763210 | Sep 2026 → Mar 2028 expected | diffuse large B-cell lymphoma, mantle cell lymphoma, marginal zone lymphoma | Vanderbilt-Ingram Cancer Center | Recruiting | No outcome recorded |
| Phase 2 | NCT06381661 | May 2026 → Jun 2028 expected | infectious disease with sepsis | Assistance Publique - Hôpitaux de Paris | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06895473 | Jun 2025 → Apr 2027 expected | hematopoietic and lymphoid system neoplasm | OHSU Knight Cancer Institute | Recruiting | No outcome recorded |
| Phase 2 | NCT04180969 | Apr 2023 | — | Wayne State University | Withdrawn | No outcome recorded Stop: Business |
| Phase 2 | NCT05160506 | Mar 2022 → Jan 2027 expected | acute pancreatitis | Beth Israel Deaconess Medical Center | Recruiting | No outcome recorded |
| Phase 2 | NCT05112354 | Dec 2019 → Jun 2021 | sudden sensorineural hearing loss | Assiut University | Completed | No outcome recorded |
| Phase 2 | NCT03710187 | Nov 2018 → Sep 2019 | infectious disease with sepsis | University of Tennessee Medical Center | Completed | No outcome recorded |
| Phase 2 | NCT03592693 | Sep 2018 → Jan 2023 | — | University of Athens | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT03422159 | Feb 2018 → Jun 2019 | infectious disease with sepsis | Community Medical Center, Toms River, NJ | Completed | Met primary |
| Phase 2 | NCT02465606 | Jul 2015 → May 2016 | atopic eczema | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 2 | NCT02689856 | May → Sep 2015 | hemorrhoid | Citius Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT02339350 | Jan 2015 → Apr 2023 | acute lymphoblastic leukemia | The Korean Society of Pediatric Hematology Oncology | Unknown | No outcome recorded |
| Phase 2 | NCT02229136 | Sep 2014 → Nov 2022 | breast cancer, stomatitis | US Oncology Research | Completed | No outcome recorded |
| Phase 2 | NCT02043587 | Jan 2014 → Apr 2022 | acute lymphoblastic leukemia | University of California, San Diego | Terminated | No outcome recorded |
| Phase 2 | NCT01859312 | May 2013 → Dec 2016 | adrenal gland hyperfunction, classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency | National Institutes of Health Clinical Center (CC) | Completed | No outcome recorded |
| Phase 2 | NCT01860664 | May 2013 → May 2016 | conjunctivitis | Koffler Vision Group | Terminated | No outcome recorded |
| Phase 2 | NCT01735617 | Dec 2012 → Dec 2013 | congenital adrenal hyperplasia | Neurocrine UK Limited | Completed | No outcome recorded |
| Phase 2 | NCT01451515 | May 2012 → May 2021 | lymphoblastic lymphoma | St. Jude Children's Research Hospital | Completed | No outcome recorded |
| Phase 2 | NCT01973855 | Jan 2012 → Mar 2015 | dengue disease, viral hemorrhagic fever | Guangzhou 8th People's Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT01460615 | Feb 2011 → Jan 2017 | pancreatitis | Tampere University Hospital | Completed | Mixed |
| Phase 2 | NCT01104025 | Apr 2010 → Nov 2015 | hemophagocytic syndrome | Children's Hospital Medical Center, Cincinnati | Completed | No outcome recorded |
| Phase 2 | NCT01036594 | Dec 2009 → Dec 2012 | prostate cancer | University of California, San Francisco | Completed | No outcome recorded |
| Phase 2 | NCT00980135 | Nov 2009 → May 2010 | atopic eczema | Bayer | Completed | No outcome recorded |
| Phase 2 | NCT00473083 | Jan 2009 → Dec 2012 | exanthem | British Columbia Cancer Agency | Completed | Missed primary |
| Phase 2 | NCT00805285 | Oct 2008 → Oct 2009 | ulcerative colitis | University of Maryland, Baltimore | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT00704262 | May 2008 → Dec 2009 | psoriasis | LEO Pharma | Completed | No outcome recorded |
| Phase 2 | NCT00657306 | May → Dec 2008 | cirrhosis of liver | University of Turin, Italy | Unknown | No outcome recorded |
| Phase 2 | NCT00621985 | Apr 2008 → Jun 2009 | congenital adrenal hyperplasia | Boston Children's Hospital | Completed | Missed primary |
| Phase 2 | NCT00732277 | Apr 2008 → Apr 2012 | infectious disease with sepsis | University Hospital Southampton NHS Foundation Trust | Completed | No outcome recorded |
| Phase 2 | NCT00476190 | Apr 2007 → Sep 2013 | acute lymphoblastic leukemia | Dana-Farber Cancer Institute | Completed | No outcome recorded |
| Phase 2 | NCT00317070 | Apr 2006 → Feb 2009 | interstitial cystitis | Nova Scotia Health Authority | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT00332163 | Apr 2006 → Jan 2008 | colorectal cancer, exanthem, toxic dermatosis | Amgen | Completed | No outcome recorded |
| Phase 2 | NCT00167544 | Nov 2005 → Jan 2009 | bronchopulmonary dysplasia, encephalomalacia | Nationwide Children's Hospital | Completed | Missed primary |
| Phase 2 | NCT00097474 | Dec 2004 → Jan 2006 | circadian rhythm sleep disorder, jet lag type | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Completed | No outcome recorded |
| Phase 2 | NCT00309894 | Apr 2004 → Nov 2007 | prostate cancer | University of California, San Francisco | Completed | No outcome recorded |
| Phase 2 | NCT00590018 | Feb 2003 → Dec 2009 | heart failure | Baylor College of Medicine | Completed | No outcome recorded |
| Phase 2 | NCT00220454 | Dec 2002 → Mar 2005 | — | Seattle Institute for Biomedical and Clinical Research | Completed | No outcome recorded |
| Phase 2 | NCT00004669 | Jun 1996 → ? | bronchopulmonary dysplasia | National Center for Research Resources (NCRR) | Completed | No outcome recorded |
| Phase 2/39 trials · 1 met primary · 2 missed | ||||||
| Phase 2/3 | NCT06496997 | Aug 2024 → Apr 2025 | acute respiratory distress syndrome | Fayoum University | Completed | No outcome recorded |
| Phase 2/3 | NCT05534334 | May → Nov 2022 | pyogenic granuloma | Beni-Suef University | Unknown | No outcome recorded |
| Phase 2/3 | NCT03682393 | Jan 2020 → Dec 2022 | atrial fibrillation | Kuopio University Hospital | Withdrawn | No outcome recorded |
| Phase 2/3 | NCT03380507 | Mar 2018 → Oct 2019 | infectious disease with sepsis | Hamad Medical Corporation | Terminated | Missed primary Stop: Business |
| Phase 2/3 | NCT03389555 | Feb 2018 → Nov 2019 | infectious disease with sepsis, metabolic disease | Beth Israel Deaconess Medical Center | Completed | Missed primary |
| Phase 2/3 | NCT02552251 | Aug 2012 → Dec 2015 | classic congenital adrenal hyperplasia | University Hospital, Caen | Unknown | No outcome recorded |
| Phase 2/3 | NCT01063569 | Feb 2010 → Dec 2012 | primary adrenal insufficiency | Haukeland University Hospital | Completed | No outcome recorded |
| Phase 2/3 | NCT01047670 | May 2008 → ? | — | Unidade de Terapia Intensiva | Unknown | No outcome recorded |
| Phase 2/3 | NCT00563303 | Nov 2006 | — | Nantes University Hospital | Completed | Met primary |
| Phase 351 trials · 6 met primary · 12 missed | ||||||
| Phase 3 | NCT07332325 | Oct 2026 → Mar 2029 expected | infectious disease with sepsis, tuberculosis | University of Virginia | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07037043 | Apr 2025 → May 2028 expected | — | Centre Hospitalier Universitaire, Amiens | Recruiting | No outcome recorded |
| Phase 3 | NCT05816226 | Jun 2023 → Jan 2026 overdue | temporomandibular joint disorder | University of the Pacific | Recruiting | No outcome recorded |
| Phase 3 | NCT05668455 | May 2023 → Dec 2025 overdue | — | Agnes | Recruiting | No outcome recorded |
| Phase 3 | NCT05299554 | Apr 2022 → Jan 2026 | congenital adrenal hyperplasia | Immedica Pharma AB | Completed | No outcome recorded |
| Phase 3 | NCT04404400 | Feb 2022 → Feb 2026 overdue | adrenocortical insufficiency | Assistance Publique - Hôpitaux de Paris | Recruiting | No outcome recorded |
| Phase 3 | NCT04821583 | Jun 2021 → Sep 2022 | multiple symmetric lipomatosis | Erasmus Medical Center | Unknown | No outcome recorded |
| Phase 3 | NCT04591990 | May 2021 → Dec 2025 overdue | post-cardiac arrest syndrome | Assistance Publique - Hôpitaux de Paris | Recruiting | No outcome recorded |
| Phase 3 | NCT04469686 | Dec 2020 → Jul 2024 | proctitis | Cristcot LLC | Completed | No outcome recorded |
| Phase 3 | NCT04359511 | Jul 2020 | COVID-19 | University Hospital, Tours | Withdrawn | No outcome recorded |
| Phase 3 | NCT04348305 | Apr → Sep 2020 | COVID-19 | Scandinavian Critical Care Trials Group | Completed | Missed primary |
| Phase 3 | NCT04134403 | Dec 2019 → Nov 2020 | infectious disease with sepsis | Baqiyatallah Medical Sciences University | Unknown | No outcome recorded |
| Phase 3 | NCT03936517 | Jul 2019 → Feb 2025 | adrenocortical insufficiency | Imperial College London | Unknown | Met primary |
| Phase 3 | NCT03773822 | Apr 2019 → Apr 2023 | cardiogenic shock | CMC Ambroise Paré | Completed | No outcome recorded |
| Phase 3 | NCT03872011 | Feb 2019 → Sep 2021 | infectious disease with sepsis | Northern Jiangsu People's Hospital | Completed | Missed primary |
| Phase 3 | NCT03509350 | Aug 2018 → Aug 2019 | infectious disease with sepsis | Emory University | Completed | Missed primary |
| Phase 3 | NCT03007147 | Aug 2017 → Jun 2026 overdue | B-cell acute lymphoblastic leukemia, T-cell acute lymphoblastic leukemia, mixed phenotype acute leukemia | Children's Oncology Group | Active not recruiting | No outcome recorded |
| Phase 3 | NCT03062280 | Aug 2016 → Jul 2022 | congenital adrenal hyperplasia | Neurocrine UK Limited | Completed | Missed primary |
| Phase 3 | NCT02735707 | Apr 2016 → Feb 2026 overdue | pneumonia | UMC Utrecht | Recruiting | Mixed |
| Phase 3 | NCT02733367 | Mar 2016 → Aug 2018 | adrenocortical insufficiency | Neurocrine UK Limited | Completed | No outcome recorded |
| Phase 3 | NCT02716818 | Feb 2016 → Jul 2018 | congenital adrenal hyperplasia | Neurocrine UK Limited | Completed | Missed primary |
| Phase 3 | NCT02517489 | Oct 2015 → Jul 2020 | — | University Hospital, Tours | Completed | No outcome recorded |
| Phase 3 | NCT02720952 | Mar 2015 → Jul 2016 | adrenocortical insufficiency | Neurocrine UK Limited | Completed | No outcome recorded |
| Phase 3 | NCT00980876 | Apr 2012 → Jan 2015 | acute otitis externa | Farmoquimica S.A. | Completed | No outcome recorded |
| Phase 3 | NCT01574612 | Mar → Dec 2012 | herpes labialis | Meda Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT02883049 | Feb 2012 → Dec 2022 | B-lymphoblastic leukemia/lymphoma, BCR-ABL1–like, central nervous system leukemia, testicular leukemia | National Cancer Institute (NCI) | Completed | Missed primary |
| Phase 3 | NCT06260462 | Jan 2012 → Sep 2022 | adrenocortical insufficiency | University of Palermo | Completed | No outcome recorded |
| Phase 3 | NCT02266589 | Nov 2011 → Oct 2013 | infectious disease with sepsis | Nanjing PLA General Hospital | Completed | No outcome recorded |
| Phase 3 | NCT01353313 | Aug 2011 → Sep 2020 | bronchopulmonary dysplasia, fetal growth restriction, pulmonary immaturity | NICHD Neonatal Research Network | Completed | Missed primary |
| Phase 3 | NCT01313221 | Apr 2011 → Dec 2012 | psoriasis | Amgen | Completed | Missed primary |
| Phase 3 | NCT01093261 | Aug 2010 → Nov 2012 | adrenocortical insufficiency, pneumonia, traumatic brain injury | Nantes University Hospital | Completed | Missed primary |
| Phase 3 | NCT01014364 | Mar 2010 → Jun 2011 | influenza, viral pneumonia | University of Versailles | Terminated | No outcome recorded |
| Phase 3 | NCT02114710 | May 2009 → Oct 2012 | — | Nanjing PLA General Hospital | Completed | No outcome recorded |
| Phase 3 | NCT00670254 | Jan 2009 → Aug 2013 | infectious disease with sepsis | Charite University, Berlin, Germany | Completed | Missed primary |
| Phase 3 | NCT00862381 | Oct 2008 → Jul 2010 | — | University Hospital, Grenoble | Completed | No outcome recorded |
| Phase 3 | NCT00729794 | Sep 2008 → Nov 2010 | cardiac arrest | University of Athens | Completed | Met primary |
| Phase 3 | NCT00691002 | May 2008 → Jan 2010 | psoriasis | LEO Pharma | Completed | Mixed |
| Phase 3 | NCT00623740 | Apr 2008 → Jan 2016 | bronchopulmonary dysplasia | Assistance Publique - Hôpitaux de Paris | Completed | Met primary |
| Phase 3 | NCT00640822 | Feb 2008 → Jun 2009 | psoriasis | LEO Pharma | Completed | No outcome recorded |
| Phase 3 | NCT00591006 | Jan 2008 → Jul 2009 | — | University of Texas Southwestern Medical Center | Completed | Met primary |
| Phase 3 | NCT00735761 | Dec 2006 → Sep 2007 | herpes labialis | Medivir | Completed | No outcome recorded |
| Phase 3 | NCT00705822 | Aug 2006 → Jul 2009 | prostate cancer | Sanofi | Terminated | No outcome recorded Stop: Enrollment |
| Phase 3 | NCT00361881 | Jul 2006 → Aug 2007 | herpes labialis | Medivir | Completed | Met primary |
| Phase 3 | NCT00358748 | Jul 2005 → May 2010 | — | University of British Columbia | Completed | No outcome recorded |
| Phase 3 | NCT00027859 | Oct 2003 → Dec 2004 | prostate cancer | Eastern Cooperative Oncology Group | Completed | No outcome recorded |
| Phase 3 | NCT01453686 | Aug 2002 → Aug 2003 | alopecia areata | The Hospital for Sick Children | Completed | Met primary |
| Phase 3 | NCT00147004 | Mar 2002 → Nov 2005 | — | Hadassah Medical Organization | Completed | Missed primary |
| Phase 3 | NCT00019409 | Oct 1999 → Jul 2001 | leukemia | National Institutes of Health Clinical Center (CC) | Withdrawn | No outcome recorded |
| Phase 3 | NCT00003436 | Jul 1998 → Dec 2005 | leukemia, myelodysplastic syndrome | Medical Research Council | Completed | No outcome recorded |
| Phase 3 | NCT00002744 | May 1996 → Mar 2007 | leukemia | Children's Oncology Group | Completed | Mixed |
| Phase 3 | NCT00001521 | Jun 1995 → Apr 2024 | congenital adrenal hyperplasia | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | Completed | Missed primary |
| Phase 442 trials · 2 met primary · 2 missed | ||||||
| Phase 4 | NCT07558811 | Apr → Dec 2026 expected | primary aldosteronism | Ruijin Hospital | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07383103 | Mar 2026 → Dec 2028 expected | infectious disease with sepsis | Northern Jiangsu People's Hospital | Recruiting | No outcome recorded |
| Phase 4 | NCT07695337 | Jan → Jul 2026 | infectious disease with sepsis | Benha University | Completed | No outcome recorded |
| Phase 4 | NCT07124650 | Sep 2025 → Dec 2026 expected | — | Saint Petersburg State University, Russia | Recruiting | No outcome recorded |
| Phase 4 | NCT07262957 | Sep 2025 → Sep 2027 expected | ampulla of vater adenocarcinoma, cholangiocarcinoma, cystic neoplasm, neuroendocrine neoplasm +3 | Academic Medical Center - University of Amsterdam | Recruiting | No outcome recorded |
| Phase 4 | NCT07248761 | Feb 2025 → Jun 2026 overdue | hyperglycemia, neonatal sepsis, patent ductus arteriosus, perinatal asphyxia +4 | Coordinación de Investigación en Salud, Mexico | Active not recruiting | No outcome recorded |
| Phase 4 | NCT06679816 | Dec 2024 → Dec 2025 overdue | pituitary gland adenoma | Beijing Tiantan Hospital | Recruiting | No outcome recorded |
| Phase 4 | NCT06435481 | Sep 2024 → Sep 2025 overdue | adrenocortical insufficiency | Hospital Universitari Vall d'Hebron Research Institute | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT06018727 | Jul 2024 → Jul 2025 | borderline personality disorder | University of North Carolina, Chapel Hill | Withdrawn | No outcome recorded |
| Phase 4 | NCT06637384 | Mar → Apr 2024 | diabetes mellitus | Rimsha Rasheed | Completed | No outcome recorded |
| Phase 4 | NCT05436535 | Nov 2022 → Apr 2025 | atopic eczema | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 4 | NCT05658692 | Oct 2022 → Oct 2023 | acute respiratory distress syndrome | Second Affiliated Hospital, School of Medicine, Zhejiang University | Unknown | No outcome recorded |
| Phase 4 | NCT05350020 | Mar 2022 → Mar 2023 | primary adrenal insufficiency | The London Clinic | Unknown | No outcome recorded |
| Phase 4 | NCT05159284 | Nov 2021 → Dec 2024 | dry eye syndrome | Laboratorios Thea, Spain | Unknown | No outcome recorded |
| Phase 4 | NCT05457296 | Jan → Apr 2021 | secondary adrenal insufficiency | University Tunis El Manar | Completed | No outcome recorded |
| Phase 4 | NCT04536662 | Oct 2020 → Sep 2022 | congenital adrenal hyperplasia | Shanghai Jiao Tong University School of Medicine | Unknown | No outcome recorded |
| Phase 4 | NCT04039815 | Dec 2019 → Dec 2020 | infectious disease with sepsis | Far Eastern Memorial Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT03896659 | Oct 2019 → Sep 2024 | major depressive disorder | University of Texas Southwestern Medical Center | Completed | No outcome recorded |
| Phase 4 | NCT03845608 | Mar → Oct 2019 | — | Cairo University | Unknown | No outcome recorded |
| Phase 4 | NCT03800264 | May → Nov 2018 | atrial fibrillation | Ain Shams University | Completed | No outcome recorded |
| Phase 4 | NCT03907865 | Mar → Nov 2018 | dry eye syndrome | Medical University of Vienna | Completed | No outcome recorded |
| Phase 4 | NCT03335124 | Sep 2017 → Dec 2018 | infectious disease with sepsis | University Medical Centre Ljubljana | Terminated | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT02282150 | Oct 2016 → Nov 2017 | secondary adrenal insufficiency | Ulla Feldt-Rasmussen | Unknown | No outcome recorded |
| Phase 4 | NCT03760835 | Aug 2016 → Dec 2026 expected | classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency | Federico II University | Recruiting | No outcome recorded |
| Phase 4 | NCT02775227 | May 2016 → Jan 2019 overdue | pancreatic neoplasm | Helsinki University Central Hospital | Active not recruiting | Missed primary |
| Phase 4 | NCT02372110 | Mar → Nov 2015 | anxiety | University of Texas at Austin | Completed | No outcome recorded |
| Phase 4 | NCT02266264 | Oct 2014 → May 2017 | hyperglycemia | Srinakharinwirot University | Completed | No outcome recorded |
| Phase 4 | NCT02044159 | Jul 2014 → Apr 2016 | — | Children's Hospital of Eastern Ontario | Completed | No outcome recorded |
| Phase 4 | NCT01070225 | Mar → Aug 2010 | asthma | University of Dundee | Completed | Missed primary |
| Phase 4 | NCT00706173 | Aug 2009 → Sep 2011 | post-traumatic stress disorder | University of California, San Diego | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT00933023 | Aug → Sep 2009 | phimosis | Chelsea and Westminster NHS Foundation Trust | Withdrawn | No outcome recorded |
| Phase 4 | NCT01399268 | Feb 2009 → Aug 2010 | — | Hospital for Special Surgery, New York | Completed | No outcome recorded |
| Phase 4 | NCT00674570 | Jan 2009 → Jun 2015 | post-traumatic stress disorder | VA Office of Research and Development | Completed | Met primary |
| Phase 4 | NCT01769339 | Jan → Jun 2009 | vulvovaginal candidiasis | Janssen Pharmaceutica | Completed | No outcome recorded |
| Phase 4 | NCT00709839 | Jun → Oct 2008 | — | Medical University of Vienna | Completed | No outcome recorded |
| Phase 4 | NCT01150409 | May 2008 → Aug 2010 | infectious disease with sepsis | The Cleveland Clinic | Terminated | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT02768740 | Apr 2008 → May 2010 | infectious disease with sepsis | Association Niçoise de Réanimation Médicale | Completed | No outcome recorded |
| Phase 4 | NCT00415701 | Nov 2006 → Dec 2009 | coronary artery disorder, mitral valve insufficiency | Insel Gruppe AG, University Hospital Bern | Completed | No outcome recorded |
| Phase 4 | NCT00149123 | Apr 2005 → Oct 2010 | — | Hospices Civils de Lyon | Completed | Met primary |
| Phase 4 | NCT00270777 | Mar 2005 → Apr 2008 | snakebite envenomation | University of Kelaniya | Completed | Mixed |
| Phase 4 | NCT00853008 | Jan 2003 → Nov 2012 | acute lymphoblastic leukemia | PETHEMA Foundation | Completed | No outcome recorded |
| Phase 4 | NCT00526305 | Jan 2000 → Apr 2005 | acute lymphoblastic leukemia | PETHEMA Foundation | Completed | No outcome recorded |
| Phase not applicable29 trials · 2 met primary · 3 missed | ||||||
| — | NCT07313670 | Jul → Dec 2025 | infectious disease with sepsis | Muhammad Aamir Latif | Completed | No outcome recorded |
| — | NCT06556277 | Sep 2024 → Feb 2026 | overnutrition | Eleonora Seelig | Completed | No outcome recorded |
| — | NCT06217939 | Jun 2024 → Jun 2026 overdue | infectious disease with sepsis | Siriraj Hospital | Recruiting | No outcome recorded |
| — | NCT04597762 | Aug 2020 → Mar 2021 | dry eye syndrome | Hospital Hietzing | Completed | No outcome recorded |
| — | NCT04465539 | Jul 2020 → Feb 2024 | — | Tanta University | Completed | No outcome recorded |
| — | NCT04280497 | Apr 2020 → Dec 2025 overdue | infectious disease with sepsis | Assistance Publique - Hôpitaux de Paris | Recruiting | No outcome recorded |
| — | NCT04160676 | Dec 2019 → Jul 2021 | infectious disease with sepsis | Tanta University | Completed | No outcome recorded |
| — | NCT04536129 | Nov 2019 → Mar 2020 | eye adnexa disorder, glaucoma | University of Molise | Completed | No outcome recorded |
| — | NCT03748537 | Jan 2017 → Dec 2019 | infectious disease with sepsis | Chiang Mai University | Completed | No outcome recorded |
| — | NCT02580240 | Sep 2015 → Sep 2016 | infectious disease with sepsis | Northern Jiangsu People's Hospital | Completed | Missed primary |
| — | NCT02552654 | Sep → Nov 2015 | — | Charite University, Berlin, Germany | Completed | No outcome recorded |
| — | NCT02691858 | Apr 2015 → Jun 2025 overdue | intussusception | Cairo University | Recruiting | No outcome recorded |
| — | NCT02402114 | Feb 2015 → Feb 2016 | post-traumatic stress disorder | Albert Einstein Healthcare Network | Withdrawn | No outcome recorded |
| — | NCT02360046 | Jan 2015 → Dec 2016 | hypopituitarism | Insel Gruppe AG, University Hospital Bern | Terminated | No outcome recorded |
| — | NCT00442494 | Oct 2012 | atrial fibrillation | Kuopio University Hospital | Terminated | Met primary |
| — | NCT02417987 | May 2012 → Aug 2014 | disease of the tendon | Bispebjerg Hospital | Completed | No outcome recorded |
| — | NCT01595386 | Apr 2012 → Nov 2013 | congenital heart disease | University of Alabama at Birmingham | Completed | Met primary |
| — | NCT01108133 | Oct 2010 → Mar 2013 | post-traumatic stress disorder | Central Institute of Mental Health, Mannheim | Completed | No outcome recorded |
| — | NCT01156480 | Sep 2009 → Nov 2012 | necrotizing enterocolitis | Endeavor Health | Terminated | No outcome recorded Stop: Enrollment |
| — | NCT00855270 | Apr 2009 → Sep 2016 | post-traumatic stress disorder | Sheba Medical Center | Unknown | Missed primary |
| — | NCT01108146 | Oct 2008 → Oct 2012 | post-traumatic stress disorder | Central Institute of Mental Health, Mannheim | Completed | Missed primary |
| — | NCT00559481 | Oct 2007 → Sep 2008 | prostate cancer | Roswell Park Cancer Institute | Withdrawn | No outcome recorded Stop: Enrollment |
| — | NCT00529841 | Jan 2007 → Sep 2008 | congenital adrenal hyperplasia | Baylor College of Medicine | Completed | No outcome recorded |
| — | NCT00396344 | Oct 2006 → Nov 2007 | infectious disease with sepsis | Dartmouth-Hitchcock Medical Center | Completed | No outcome recorded |
| — | NCT00451230 | Jun 2005 | cocaine dependence | National Institute on Drug Abuse (NIDA) | Completed | No outcome recorded |
| — | NCT00172354 | Oct 2004 → May 2006 | cardiac arrest | National Taiwan University Hospital | Completed | No outcome recorded |
| — | NCT00049569 | Jan 2003 → Mar 2006 | T-cell childhood acute lymphocytic leukemia | National Cancer Institute (NCI) | Completed | No outcome recorded |
| — | NCT00186264 | Aug 2002 → Apr 2006 | major depressive disorder | Stanford University | Completed | No outcome recorded |
| — | NCT00442390 | Jan 2002 → Jan 2003 | primary adrenal insufficiency | University of Aarhus | Completed | No outcome recorded |
| Comparator or background therapy235 trials | ||||||
| Phase 0 | NCT07059975 Background | Oct 2025 → Oct 2028 expected | childhood acute myeloid leukemia | Joanna Yi | Recruiting | No outcome recorded |
| Phase 0 | NCT06942039 Background | Sep 2025 → Dec 2030 expected | atypical teratoid rhabdoid tumor, childhood medulloblastoma, embryonal tumor with multilayered rosettes, ependymoblastoma +5 | C17 Council | Recruiting | No outcome recorded |
| Phase 0 | NCT05674253 Comparator | Dec 2022 → Jun 2023 | atrial fibrillation | Ain Shams University | Unknown | No outcome recorded |
| Phase 0 | NCT05008146 Background | Dec 2020 → Sep 2028 expected | substance-related disorder | Rajesh Narendran | Recruiting | No outcome recorded |
| Phase 0 | NCT02256865 Comparator | Oct 2014 → Nov 2017 | — | Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center | Completed | No outcome recorded |
| Show all 235 trials opens the full record — a long page | ||||||
News releases announcing trial results or a regulatory action · 20
| Date | Issuer | Release |
|---|---|---|
| 2026-05-08 | Immedica Pharma AB | Regulatory Efmody® (modified-release hydrocortisone) receives MHRA approval for adrenal insufficiency in the UK immedica.com ↗ |
| 2026-04-07 | Immedica Pharma AB | Regulatory Efmody® (modified-release hydrocortisone) granted extension of indication for adrenal insufficiency immedica.com ↗
Immedica Pharma AB is pleased to announce that the European Commission (EC) has granted extension of indication for Efmody® (modified-release hydrocortisone) to include treatment of adrenal insufficiency (AI) in adolescents aged 12 years and over and adults. |
| 2026-02-13 | AstraZeneca | Results Positive and clinically meaningful results from the Phase III KALOS and LOGOS trials for Breztri in patients with uncontrolled asthma published in The Lancet Respiratory Medicine astrazeneca.com ↗
In the pooled analysis of KALOS and LOGOS, Breztri also demonstrated clinically meaningful reductions in the annualised rate of severe asthma exacerbations versus ICS/LABA medicines in patients with or without a recent asthma exacerbation. |
| 2025-10-29 | AstraZeneca | Results Alexion data presented at 2025 AANEM Annual Meeting and MGFA Scientific Session underscores pioneering C5 inhibition leadership in gMG astrazeneca.com ↗
An encore oral presentation will highlight a retrospective study of patients with gMG showing that corticosteroid-related toxicity was higher in patients with ≥3 months’ continuous use of corticosteroids versus those with <3 months’ continuous use, or no use at all. |
| 2024-10-10 | AstraZeneca | Results Alexion, AstraZeneca Rare Disease data at the 2024 AANEM Annual Meeting and MGFA Scientific Session further demonstrate advancement in gMG care astrazeneca.com ↗
At the MGFA Scientific Session an analysis of global gMG registry data will demonstrate a reduced oral corticosteroid (OCS) burden in adults treated with Soliris or Ultomiris . |
| 2023-06-15 | Neurocrine Biosciences | Results Diurnal Ltd., a Neurocrine Biosciences Company, Presents Phase 3 Extension Study Data for Modified-Release Hydrocortisone in Patients with Congenital Adrenal Hyperplasia at ENDO 2023 gcs-web.com ↗
The number of patients achieving lower androgen levels while receiving ≤25 mg of hydrocortisone per day increased significantly, with 48 percent of the subjects achieving 17-OHP levels <36 nmol/L compared with 31 percent at baseline. |
| 2020-07-28 | AbbVie | Results Third Pivotal Phase 3 Study Shows RINVOQ™ (upadacitinib) Plus Topical Corticosteroids Improves Skin and Itch Symptoms in Atopic Dermatitis Patients abbvie.com ↗
AbbVie (NYSE: ABBV) today announced upadacitinib (15 mg and 30 mg, once daily) plus topical corticosteroids (TCS) met the co-primary endpoints and all secondary endpoints in AD Up, the third pivotal Phase 3 study of RINVOQ in atopic dermatitis. |
| 2019-08-16 | Lupin Limited | Regulatory Lupin receives U.S. FDA approval for Hydrocortisone Valerate Cream lupin.com ↗
Mumbai, Baltimore: Pharma major Lupin Limited (Lupin) announced that it has received approval for its Hydrocortisone Valerate Cream USP, 0.2% from the United States Food and Drug Administration (U.S. FDA). |
| 2019-05-20 | AstraZeneca | Results New data show Symbicort reduces attacks in mild asthma when used as an anti-inflammatory reliever astrazeneca.com ↗
Symbicort Turbuhaler demonstrated a 51% reduction in the rate of annual asthma exacerbations compared to albuterol. |
| 2018-10-22 | Faron Pharmaceuticals Ltd | Results INTEREST trial update presented at ESICM faron.com ↗
However, concomitant exposure of human lung tissue samples to hydrocortisone in ex vivo culture conditions prevents Traumakine induced CD73 expression in lung capillaries |
| 2016-02-01 | Citius Pharmaceuticals, Inc. | Results Citius Pharmaceuticals Announces Results from Phase 2a Trial of Hydrocortisone and Lidocaine Combination Cream in Patients with Grade I and II Hemorrhoids citiuspharma.com ↗
Citius Pharmaceuticals, Inc. (OTCQB: CTXR) today announced top line data from the first Phase 2a clinical trial of hydrocortisone acetate (HC) and lidocaine hydrochloride (L) as single agents and in combination (HC+L) in patients with grade I and II hemorrhoids. |
| 2010-12-08 | Medivir | Results Medivir’s U.S. commercialisation partner Meda presents positive Xerese™ data at ASHP medivir.com ↗
The data showed that Xerese™/ Xerclear® was well tolerated and did not give rise to acyclovir resistant virus. |
| 2010-10-26 | Medivir | Results Medivir’s U.S. commercialisation partner Meda presents positive Xerese™ data at the AOA's Osteopathic Medical Conference and Exposition medivir.com ↗
The study found that the combination was well tolerated and had a favourable safety profile. |
| 2010-06-02 | AstraZeneca | Regulatory FDA updates US product labels for LABA-containing medications including AstraZeneca’s SYMBICORT astrazeneca.com ↗
The updated label for combination asthma medications, including SYMBICORT, provides guidance on how these products should be prescribed to treat asthma, including: |
| 2009-12-21 | Medivir | Regulatory First OTC pharmaceutical that can prevent herpes cold sores approved in Sweden medivir.com ↗
The Swedish Medical Products Agency has now approved Xerclear™ for treatment of cold sores. |
| 2009-08-03 | Medivir | Regulatory The US FDA approves Lipsovir® for marketing and sales in US medivir.com ↗ |
| 2008-12-08 | Medivir | Regulatory Marketing Authorization Application for Lipsovir® now validated by American and European regulatory authorities medivir.com ↗
Medivir announced today that the American (FDA) and European regulatory authorities have validated the NDA and Marketing Authorization Application for Lipsovir®. |
| 2008-10-23 | Medivir | Regulatory Marketing Authorization Application for Lipsovir® submitted to European regulatory authorities. medivir.com ↗
Medivir has now submitted an application for marketing authorization to the European regulatory authorities for Lipsovir®, a topical product for prevention and treatment of cold sores. |
| 2008-10-01 | Medivir | Regulatory New Drug Application (NDA) for Lipsovir® submitted to US FDA medivir.com ↗
Medivir has today submitted an NDA to the US Food & Drug Administration (FDA) for Lipsovir®, a topical product for prevention and treatment of cold sores. |
| 2008-03-19 | Medivir | Results Lipsovir® prevents cold sores. Phase III clinical trial results first to show prevention by early treatment. medivir.com ↗
Treatment with Lipsovir® prevented the development of cold sores in 42% of patients. |
All press releases naming this drug 20 releases
Evidence & citations 33 cited values
Every value below carries the sentence it was read from. 446 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Hydrocortisone | “Patients were randomized to receive either preservative-free hydrocortisone 0.335% (Softacort, Laboratories Thea, France) for 12 days four times daily followed by 2 days twice...” PMID 31741283 ↗ Nov 2019415“Pre-emptive skin treatment included a skin moisturizer (eg, Lubriderm), sunscreen (free of paraaminobenzoic acid (PABA), skin protection factor (SPF) 15 or higher,...” NCT00332163 ↗ “Patients were randomly assigned in a 1:1 ratio to either replace prednisone with 20 mg/day of hydrocortisone for 3 months, then reduce to 10 mg/day for 3 months before...” PMID 39874233 ↗ Jan 2025 “Intrathecal administration of 2nd, 3rd, and 4th doses of methotrexate 15 mg and hydrocortisone 50mg on day 2 or 3 of 2nd, 3rd, and 4th cycles of immunochemotherapy with...” NCT03123718 ↗ “Intrathecal chemotherapy will consist of either single-agent cytarabine or methotrexate, or a combination of methotrexate, cytarabine, and hydrocortisone, at appropriate...” NCT04029688 ↗ “Recommended TCS include triamcinolone acetonide 0.1% cream or fluocinolone acetonide 0.025% ointment as medium potency topical corticosteroids and hydrocortisone 1% cream as...” NCT03568318 ↗ “Patients received bisoprolol as group (A) in addition hydrocortisone 100 mg intravenously is given in the evening of the operation and then 100 mg every eight hours during the...” NCT03800264 ↗ “Agents for intrathecal (IT) chemotherapy, central nervous system (CNS)-1/2: IT methotrexate chemotherapy, or CNS-3: triple intrathecal (ITT) methotrexate, hydrocortisone, cytarabine.” NCT04501614 ↗ “This first ever study in patients with CAH is a pharmacokinetic/pharmacodynamic study comparing Chronocort to Cortef, the conventional immediate-release form of hydrocortisone.” NCT00519818 ↗ “hydrocortisone 1% cream (HCT) was applied twice daily for 4 weeks on one side of forehead skin without clinical signs of AD and pimecrolimus 1% cream (PIM) on the other.” PMID 21771098 ↗ Jul 2011 “Treatment A is 10 mg hydrocortisone (2 tablets Cortef, 5 mg each),Stress-dose will be taken per os one time 2 tablets 10 mg of Cortef 60 min before start of exercise.” NCT01847690 ↗ |
| Known as | 17-Hydroxycorticosterone | “Hydrocortisone (17-Hydroxycorticosterone) is the preferred cortisol replacement.” NCT06435481 ↗ |
| Known as | Chronocort | “Chronocort (hydrocortisone modified-release hard gelatin capsules for oral administration - 5mg and 10mg” NCT05222152 ↗1“Chronocort® modified release hydrocortisone” NCT03062280 ↗ |
| Known as | Cortef | “This was a two-part, single centre, open-label, randomised, single dose, two-period, crossover study to evaluate the bioavailability of Infacort® versus Cortef® immediate...” NCT03311932 ↗4“Hydrocortisone (Cortef™) 20mg tablet administered on one day.” NCT03015246 ↗ “Cortef (hydrocortisone)” NCT01063569 ↗ |
| Known as | Cortenema | “Hydrocortisone retention enema (Cortenema) administered rectally as a single dose; each dose unit delivers 100 mg of hydrocortisone per 60 mL.” NCT02671058 ↗ |
| Known as | cortisol | “This study will examine the effects of cortisol (hydrocortisone), melatonin, a combination of cortisol and melatonin, and placebo (an inactive substance) on jet lag symptoms.” NCT00097474 ↗2“Hydrocortisone is the pharmaceutical term for cortisol, the principal glucocorticoid secreted by the adrenal gland” NCT02700828 ↗ “intravenous hydrocortisone (cortisol) challenge” NCT03302416 ↗ |
| Known as | CORTIVIS | “Hydrocortisone (CORTIVIS ®)” NCT04536129 ↗ |
| Known as | HCT | “hydrocortisone 1% cream (HCT) was applied twice daily for 4 weeks on one side of forehead skin without clinical signs of AD and pimecrolimus 1% cream (PIM) on the other.” PMID 21771098 ↗ Jul 2011 |
| Known as | High Volume injection | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02417987 ↗ |
| Known as | Hy-Cortisone Injection | “single dose Hy-Cortisone Injection 250 mg (Generic name: Hydrocortisone Sodium Succinate, Cirin Pharmaceuticals Pakistan) intramuscularly after extraction” NCT06637384 ↗ |
| Known as | Hydrocortison | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01691209 ↗ |
| Known as | hydrocortisone acetate | “This cream consists of lidocaine (5% w/w), hydrocortisone acetate (7.5% w/w), aluminium sub-acetate (3.5% w/w), and zinc oxide (18% w/w).” NCT02301052 ↗9“Hydrocortisone or hydrocortisone/hydrocortisone acetate administered via intramuscular injection as rescue medication.” NCT06979596 ↗ “Anucort HC TM (Hydrocortisone Acetate) 25mg Rectal Suppositories” NCT01913158 ↗ |
| Known as | HYDROCORTISONE HEMISUCCINATE | “Hydrocortisone hemisuccinate (Hydrocortisone Upjohn) was supplied as a powder in 100 mg vials to be reconstituted with 2 ml of sterile water diluent.” NCT02768740 ↗3“HYDROCORTISONE HEMISUCCINATE Vials with lyophilisate (100mg hydrocortisone) are provided by SERB laboratory.” NCT04591990 ↗ “Hydrocortisone hemisuccinate (Roussel-Uclaf, Romainville, France), 50 mg intravenously every 6 hrs” NCT02266589 ↗ “Hydrocortisone hemisuccinate (Roussel-Uclaf, Romainville, France), 50 mg intravenously every 6 hrs” NCT02114710 ↗ |
| Known as | Hydrocortisone immediate release tablet | “Hydrocortisone immediate release tablet” NCT00519818 ↗ |
| Known as | Hydrocortisone modified-release hard capsule | “Hydrocortisone modified-release hard capsule” NCT05299554 ↗ |
| Known as | Hydrocortisone sodium acetate | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00529841 ↗ |
| Known as | Hydrocortisone sodium succinate | “The Children's Cancer Group (CCG) 1952 clinical trial for children with standard-risk acute lymphoblastic leukemia (SR-ALL) compared intrathecal (IT) methotrexate (MTX) with IT...” PMID 16609069 ↗ Apr 200617“Hydrocortisone sodium succinate for intravenous administration (unpreserved, Solu-Cortef plain, Pfizer®, reconstituted with unpreserved normal saline to avoid exposure to the...” NCT01353313 ↗ “hydrocortisone (hydrocortisone sodium succinate, plain; will not have benzyl alcohol)” NCT01954056 ↗ “Generic name: Hydrocortisone Sodium Succinate, Cirin Pharmaceuticals Pakistan” NCT06637384 ↗ “* Hydrocortisone sodium succinate (Solucortef) 100 mg” NCT00317070 ↗ “Drug: Hydrocortisone Sodium Succinate” NCT05761171 ↗ |
| Known as | Hydrocortisone Upjohn | “Hydrocortisone hemisuccinate (Hydrocortisone Upjohn) was supplied as a powder in 100 mg vials to be reconstituted with 2 ml of sterile water diluent.” NCT02768740 ↗ |
| Known as | Hydrocortisone-21-acetate | “Hydrocortisone-21-acetate creme (25%) 15 microl/cm2 b.i.d.” NCT01055249 ↗ |
| Known as | Infacort | “This was a two-part, single centre, open-label, randomised, single dose, two-period, crossover study to evaluate the bioavailability of Infacort® versus Cortef® immediate...” NCT03311932 ↗2“Infacort® is a dry granule formulation of hydrocortisone stored in capsules that will be available in different strengths (0.5, 1.0, 2.0 and 5.0mg).” NCT02720952 ↗ “Infacort® is a dry granule formulation of hydrocortisone stored in capsules available in different strengths (0.5, 1.0, 2.0 and 5.0 mg).” NCT02733367 ↗ |
| Known as | LDH | “low dose hydrocortisone (LDH)” NCT03237689 ↗ |
| Known as | MR-HC | “modified-release hydrocortisone (MR-HC), which mimics physiologic cortisol secretion” PMID 33527139 ↗ Apr 2021 |
| Known as | NSC-10483 | “Antiandrogen stopped; plus Ketoconazole, KCZ; Hydrocortisone, HC, NSC-10483.” NCT00002760 ↗ |
| Known as | Plenadren | “Thereafter participants are shifted to modified release hydrocortisone (Plenadren) once daily (OD), on a dose as per Summary of Product Characteristics (SmPC).” NCT02282150 ↗3“Plenadren (modified release hydrocortison) 20-25 or 30 mg oral tablets will be administered once-daily at 8.00 AM in the fasting state” NCT02277587 ↗ “Plenadren (hydrocortisone modified-release tablets for oral administration - 5mg and 20mg” NCT05222152 ↗ “Dual release hydrocortisone (plenadren)” NCT03760835 ↗ |
| Known as | Softacort | “Patients were randomized to receive either preservative-free hydrocortisone 0.335% (Softacort, Laboratories Thea, France) for 12 days four times daily followed by 2 days twice...” PMID 31741283 ↗ Nov 2019 |
| Known as | solu-cortef | “These patients will receive standard therapy for sepsis plus Hydrocortisone (Solucortef®, E.I.P.I.co. under license of Pfizer) at dose 50mg every 6 hours by Intra venous route.” NCT04492280 ↗6“treated with intravenous steroid, Solu-Cortef 50mg q6h taper down when hemodynamic stable” NCT01423864 ↗ “* Hydrocortisone sodium succinate (Solucortef) 100 mg” NCT00317070 ↗ “Hydrocortisone Injection (also known as solu-cortef)” NCT04037605 ↗ “Hydrocortisone (Solucortef)” NCT01859312 ↗ |
| Known as | Solu-Cortef plain | “Hydrocortisone sodium succinate for intravenous administration (unpreserved, Solu-Cortef plain, Pfizer®, reconstituted with unpreserved normal saline to avoid exposure to the...” NCT01353313 ↗ |
| Known as | SOLU-CORTEF- hydrocortisone sodium succinate injection | “SOLU-CORTEF- hydrocortisone sodium succinate injection” NCT03401398 ↗ |
| Known as | Solucortif | “hydrocortisone (Solucortif® 100 mg , vial, dried powder Pfizer, Egypt) 50 mg diluted in 5 ml normal saline IV / 6 h” NCT04160676 ↗ |
| Known as | therapeutic hydrocortisone | “Drug: therapeutic hydrocortisone” NCT00002756 ↗ |
| Action | Restore | “Glucocorticoid needed to replace cortisol deficiency.” NCT00001521 ↗ |
| Modality | Other / unclassified | “intravenous corticosteroid administration after cardiac surgery” NCT00442494 ↗ |
| Route | Oral | “low-dose hydrocortisone (6-8 mg/m\^2/day orally)” NCT00001521 ↗ |